Healthcare News

Provn requires online intake and independent clinician review before prescribing compounded low-dose naltrexone, which is not FDA-approved for weight loss.

FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability  Approval...

Highlights The Enterprise division delivered organic revenue growth of -7%, while the organic revenue growth excl. FalCom ended at -3%. The development reflects continued strong growth in North...

As a consequence of strong improvements in the second quarter, and an assumption of continued improvements in the second half of the year (including expected refunds of tariffs), GN Store Nord is...

COPENHAGEN, Denmark – August 19, 2026. Novonesis delivered strong first half of 2026 at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% (previously 5-7%), and the...

Strong first half year at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% and the adjusted EBITDA margin expected at the higher end of the 37-38% range. Inaugural share...

The Board of Directors of Novonesis has approved an inaugural multi-year share buyback program in a total amount of EUR 1 billion to be initiated during the second half of 2026 and expected to be...

Novonesis increases its full year 2026 organic sales growth outlook from 5-7% to now 7-8% based on a stronger performance so far in the year and the expectations for the rest of the year. Following...

Genome BC-funded projects cover off-the-shelf pharmacogenetic testing, genetically-informed nutrition planning, and predicting therapies for blood cancers.

Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 millionContinued...